回盛生物(300871)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300871 回盛生物

已收盘 01-12 15:00:00

{"stockData":{"symbol":"300871","market":"SZ","secType":"STK","nameCN":"回盛生物","latestPrice":23.12,"timestamp":1768201389000,"preClose":22.63,"halted":0,"volume":18075017,"delay":0,"changeRate":0.0217,"floatShares":202000000,"shares":202000000,"eps":1.0647,"marketStatus":"已收盘","change":0.49,"latestTime":"01-12 15:00:00","open":23.28,"high":23.5,"low":22.22,"amount":411000000,"amplitude":0.0566,"askPrice":23.13,"askSize":342,"bidPrice":23.12,"bidSize":288,"shortable":0,"etf":0,"ttmEps":1.0647,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768267800000},"marketStatusCode":5,"adr":0,"adjPreClose":22.63,"symbolType":"stock","openAndCloseTimeList":[[1768181400000,1768188600000],[1768194000000,1768201200000]],"highLimit":24.89,"lowLimit":20.37,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":202332557,"isCdr":false,"pbRate":2.17,"roa":"--","peRate":21.715037,"roe":"10.35%","epsLYR":-0.1215,"committee":0.028942,"marketValue":4678000000,"turnoverRate":0.0893,"status":0,"floatMarketCap":4678000000},"requestUrl":"/m/hq/s/300871","defaultTab":"news","newsList":[{"id":"2602271552","title":"股市必读：回盛生物（300871）预计2025年全年归属净利润盈利2.35亿元至2.71亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602271552","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602271552?lang=zh_cn&edition=full","pubTime":"2026-01-12 01:47","pubTimestamp":1768153633,"startTime":"0","endTime":"0","summary":"交易信息汇总资金流向1月9日主力资金净流出1269.93万元；游资资金净流出1557.79万元；散户资金净流入2827.72万元。业绩披露要点业绩预告回盛生物发布业绩预告，预计2025年全年归属净利润盈利2.35亿元至2.71亿元。公司公告汇总武汉回盛生物科技股份有限公司2025年度业绩预告武汉回盛生物科技股份有限公司预计2025年度归属于上市公司股东的净利润为23,500万元至27,100万元，较上年同期扭亏为盈，同比增长1,265.93%至1,444.54%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200000765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871"],"gpt_icon":0},{"id":"2602230021","title":"回盛生物（300871）披露2025年度业绩预告，1月9日股价上涨0.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602230021","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602230021?lang=zh_cn&edition=full","pubTime":"2026-01-10 08:56","pubTimestamp":1768006561,"startTime":"0","endTime":"0","summary":"公司近日发布《武汉回盛生物科技股份有限公司2025年度业绩预告》，预计2025年度归属于上市公司股东的净利润为23,500万元至27,100万元，较上年同期扭亏为盈，同比增长1,265.93%至1,444.54%。扣除非经常性损益后的净利润预计为21,250万元至24,850万元，同比增长1,408.61%至1,630.30%。此外，可转换公司债券提前赎回导致财务费用减少，非经常性损益对净利润影响约为2,250万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260110/31931455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","300871"],"gpt_icon":0},{"id":"2602236073","title":"回盛生物(300871.SZ)发预盈，预计2025年度归母净利润2.35亿元至2.71亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602236073","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602236073?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:13","pubTimestamp":1767946396,"startTime":"0","endTime":"0","summary":"智通财经APP讯，回盛生物(300871.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润2.35亿元至2.71亿元，扭亏为盈;扣除非经常性损益后的净利润2.13亿元至2.49亿元。报告期内，公司积极开拓海内外市场，营业收入实现国内、国外双增长。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"回盛生物(300871.SZ)发预盈，预计2025年度归母净利润2.35亿元至2.71亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300871"],"gpt_icon":0},{"id":"2601844958","title":"回盛生物：公司定增项目处于审核阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2601844958","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601844958?lang=zh_cn&edition=full","pubTime":"2026-01-07 08:42","pubTimestamp":1767746531,"startTime":"0","endTime":"0","summary":"证券之星消息，回盛生物(300871)01月06日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，请问贵公司增发事项为何迟迟没有落地，目前进行到哪一步了？预计需要多久能够完成呢？回盛生物回复：尊敬的投资者，您好！公司定增项目处于审核阶段，相关进展情况公司将严格按照相关法律法规的规定履行信息披露义务。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700004996.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"gpt_icon":0},{"id":"2593507448","title":"股市必读：回盛生物（300871）12月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2593507448","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593507448?lang=zh_cn&edition=full","pubTime":"2025-12-24 04:32","pubTimestamp":1766521933,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘，回盛生物报收于20.73元，下跌0.81%，换手率1.72%，成交量3.48万手，成交额7216.14万元。关于使用部分闲置募集资金进行现金管理的公告武汉回盛生物科技股份有限公司于2025年12月23日召开第四届董事会第三次会议，审议通过使用部分闲置募集资金进行现金管理的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400002968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"gpt_icon":0},{"id":"2593504416","title":"回盛生物（300871）披露使用部分闲置募集资金进行现金管理，12月23日股价下跌0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593504416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593504416?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:41","pubTimestamp":1766500885,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘，回盛生物报收于20.73元，较前一交易日下跌0.81%，最新总市值为41.94亿元。该股当日开盘20.91元，最高21.05元，最低20.57元，成交额达7216.14万元，换手率为1.72%。公司近日发布公告称，于2025年12月23日召开第四届董事会第三次会议，审议通过《关于使用部分闲置募集资金进行现金管理的议案》。截至2025年11月30日，公司累计使用可转债募集资金66,090.19万元，募集资金余额为4,365.69万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300040977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"gpt_icon":0},{"id":"2593649851","title":"回盛生物：原料药产能利用率较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2593649851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593649851?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:24","pubTimestamp":1766478286,"startTime":"0","endTime":"0","summary":"证券之星消息，回盛生物(300871)12月23日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好:贵公司自从今年7月技改后，至现在12月中，目前泰乐菌素和泰万菌素原料药的总产能利用率是多少？是否达到满产满销状态？回盛生物回复：尊敬的投资者，您好！公司根据市场需求合理安排生产计划，原料药产能利用率较高，公司将在年度报告中披露原料药业务的经营情况。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300023009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"gpt_icon":0},{"id":"2585452367","title":"回盛生物：二级市场股价受多种因素综合影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2585452367","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585452367?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:36","pubTimestamp":1763973369,"startTime":"0","endTime":"0","summary":"证券之星消息，回盛生物(300871)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好。投资者情绪低迷是不是由低价增发引起的？为何贵公司收益不行的时候股价破净破发，收益好转了依旧破发下跌？全市场处于同一国情，为何贵公司市值还比不过同行业的ST绿康？回盛生物回复：尊敬的投资者您好！二级市场股价受宏观经济环境、市场波动、投资者情绪、公司经营情况等多种因素的综合影响。公司将聚焦主业，持续做好经营管理工作，提升公司竞争力与盈利能力。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400018028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"gpt_icon":0},{"id":"2583502340","title":"回盛生物（300871）披露关于控股股东部分股份解除质押的公告，11月14日股价下跌0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583502340","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583502340?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:26","pubTimestamp":1763130381,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，回盛生物报收于22.02元，较前一交易日下跌0.14%，最新总市值为44.55亿元。公司近日发布公告称，控股股东武汉统盛投资有限公司近日解除部分股份质押，合计解除质押4,200,000股，占公司总股本的2.08%。本次解除质押后，武汉统盛投资有限公司累计质押股份为2,000,000股，占其持股比例的2.42%，占公司总股本的0.99%。上述股份解除质押后，控股股东暂无平仓风险或被强制过户风险，不会对公司生产经营、控制权稳定造成影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400041727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"gpt_icon":0},{"id":"2583448539","title":"回盛生物：前三季度营收与净利润实现新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2583448539","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583448539?lang=zh_cn&edition=full","pubTime":"2025-11-13 11:33","pubTimestamp":1763004800,"startTime":"0","endTime":"0","summary":"证券之星消息，回盛生物11月12日在投资者关系平台上答复投资者关心的问题。公司对外积极开拓市场，对内提升经营管理水平，在销售收入增长的同时，进一步优化生产成本，毛利率逐步改善，今年前三季度取得了较好的经营业绩，营业收入与净利润实现了新突破。二级市场股价受宏观经济环境、市场波动、投资者预期和情绪等多种因素的综合影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300016711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871"],"gpt_icon":0},{"id":"2582382829","title":"回盛生物：有部分原料药出口到台湾地区","url":"https://stock-news.laohu8.com/highlight/detail?id=2582382829","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582382829?lang=zh_cn&edition=full","pubTime":"2025-11-10 17:15","pubTimestamp":1762766115,"startTime":"0","endTime":"0","summary":"证券之星消息，回盛生物(300871)11月10日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好。回盛作为曾经的台湾兽药第一品牌引进武汉，现在在台湾还有市场份额吗？回盛生物回复：尊敬的投资者，您好！目前，公司有部分原料药出口到台湾地区。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000022220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"gpt_icon":0},{"id":"2582829867","title":"回盛生物：新华星股权改革为激发团队积极性","url":"https://stock-news.laohu8.com/highlight/detail?id=2582829867","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582829867?lang=zh_cn&edition=full","pubTime":"2025-11-10 17:15","pubTimestamp":1762766114,"startTime":"0","endTime":"0","summary":"新华星目前主要经营非公司核心业务，销售收入占比小，业务模式处于探索和转型期。为激发经营团队积极性，推进新兴业务或微小业务板块发展壮大，公司对部分板块进行股权改革试点，由团队负责人及骨干成员出资入股，增强团队责任意识和主观能动性，形成权责利的平衡，该变革不涉及利润转移问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000022219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"gpt_icon":0},{"id":"2581715720","title":"回盛生物：加快宠物药品板块布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2581715720","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581715720?lang=zh_cn&edition=full","pubTime":"2025-11-05 11:36","pubTimestamp":1762313785,"startTime":"0","endTime":"0","summary":"证券之星消息，回盛生物11月04日在投资者关系平台上答复投资者关心的问题。管理层是否有能力开启第二增长曲线，摆脱对猪周期的依赖？谢谢回盛生物回复：尊敬的投资者，您好！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500014053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"gpt_icon":0},{"id":"2581715027","title":"回盛生物：越南生产基地设计产能为1,500吨/年","url":"https://stock-news.laohu8.com/highlight/detail?id=2581715027","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581715027?lang=zh_cn&edition=full","pubTime":"2025-11-05 11:36","pubTimestamp":1762313785,"startTime":"0","endTime":"0","summary":"证券之星消息，回盛生物(300871)11月04日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好，越南生产基地产能设计是多少？目前实际产量是多少？谢谢回盛生物回复：尊敬的投资者，您好！越南生产基地主要生产化药制剂类产品，设计产能为1,500吨/年。目前，处于投产初期。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500014051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"gpt_icon":0},{"id":"2581871576","title":"回盛生物：今年取得6个制剂类新兽药","url":"https://stock-news.laohu8.com/highlight/detail?id=2581871576","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581871576?lang=zh_cn&edition=full","pubTime":"2025-11-05 11:36","pubTimestamp":1762313778,"startTime":"0","endTime":"0","summary":"证券之星消息，回盛生物11月04日在投资者关系平台上答复投资者关心的问题。谢谢回盛生物回复：尊敬的投资者，您好！今年公司取得了6个制剂类新兽药，其中醋酸氯己定软胶囊、恩康唑溶液两个新产品填补了国内相关领域空白。新产品的获批有利于提升公司市场竞争力，但新产品的推广需要市场的逐步接受。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500014048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"gpt_icon":0},{"id":"2581715496","title":"回盛生物：秋冬季节兽药需求相对较多","url":"https://stock-news.laohu8.com/highlight/detail?id=2581715496","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581715496?lang=zh_cn&edition=full","pubTime":"2025-11-05 11:33","pubTimestamp":1762313595,"startTime":"0","endTime":"0","summary":"证券之星消息，回盛生物(300871)11月04日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好，请问四季度是否是传统的旺季？按照过往情况，公司在四季度的业绩是否是一年的高点？谢谢回盛生物回复：尊敬的投资者，您好！一般秋冬季节动物易生病，兽药需求会相对多一些，公司经营情况有一定季节性。但影响经营业绩的因素较多，不是唯一参考因素。请您注意投资风险。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500013836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"gpt_icon":0},{"id":"2579336191","title":"回盛生物：原料药出口覆盖欧洲东欧国家","url":"https://stock-news.laohu8.com/highlight/detail?id=2579336191","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579336191?lang=zh_cn&edition=full","pubTime":"2025-10-30 15:57","pubTimestamp":1761811032,"startTime":"0","endTime":"0","summary":"证券之星消息，回盛生物(300871)10月30日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好，欧洲禽流感爆发，公司是否有出口欧洲的酒石酸泰乐菌素？出口量有多少？谢谢回盛生物回复：尊敬的投资者，您好！公司原料药的销售出口网络覆盖了亚洲、美洲、欧洲、非洲等20余个国家和地区。其中，欧洲主要是东欧国家，出口量较小。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000027230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"gpt_icon":0},{"id":"2579199918","title":"回盛生物：前三季度营收与净利润实现新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2579199918","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579199918?lang=zh_cn&edition=full","pubTime":"2025-10-30 15:51","pubTimestamp":1761810676,"startTime":"0","endTime":"0","summary":"证券之星消息，回盛生物10月30日在投资者关系平台上答复投资者关心的问题。公司对外积极开拓市场，对内提升经营管理水平，在销售收入增长的同时，进一步优化生产成本，毛利率逐步改善，今年前三季度取得了较好的经营业绩，营业收入与净利润实现了新突破。二级市场股价受宏观经济环境、市场波动、投资者预期和情绪等多种因素的综合影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000026443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871"],"gpt_icon":0},{"id":"2578528119","title":"回盛生物：10月28日接受机构调研，国海证券、天风证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2578528119","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578528119?lang=zh_cn&edition=full","pubTime":"2025-10-28 20:33","pubTimestamp":1761654796,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年10月28日回盛生物发布公告称公司于2025年10月28日接受机构调研，国海证券、天风证券、驼铃资产、方正富邦、西南证券、兴业证券、招商证券、中信证券、国信证券、华安证券、华创证券、华福证券、华西证券、华鑫证券、开源证券、申银万国研究所参与。公司拥有独立、专业化的宠物药品研发团队，今年已取得 2项宠物用新兽药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800039686.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0174","BK0028","BK0183","300871","BK0276","BK0239","000750","BK0188","601162"],"gpt_icon":0},{"id":"2578966621","title":"股市必读：回盛生物三季报 - 第三季度单季净利润同比增长1575.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578966621","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578966621?lang=zh_cn&edition=full","pubTime":"2025-10-28 01:24","pubTimestamp":1761585851,"startTime":"0","endTime":"0","summary":"来自股本股东变化：截至2025年9月30日股东户数环比下降10.03%，户均持股增至9567股，筹码集中度提升。来自业绩披露要点：2025年第三季度归母净利润同比增长1575.79%，盈利能力显著增强。股本股东变化股东户数变动截至2025年9月30日公司股东户数为2.12万户，较6月30日减少2358.0户，减幅为10.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800001582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768210314753,"stockEarnings":[{"period":"1week","weight":0.0917},{"period":"1month","weight":0.1762},{"period":"3month","weight":0.0609},{"period":"6month","weight":0.0904},{"period":"1year","weight":1.4085},{"period":"ytd","weight":0.0917}],"compareEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":0.0564},{"period":"3month","weight":0.0573},{"period":"6month","weight":0.1739},{"period":"1year","weight":0.2831},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"武汉回盛生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"21150人(较上一季度减少10.03%)","perCapita":"9566股","listingDate":"2020-08-24","address":"湖北省武汉市东西湖区新沟街道办事处油纱路52号","registeredCapital":"20233万元","survey":"　　武汉回盛生物科技股份有限公司的主营业务是兽用药品(包括化药制剂、原料药、中药制剂)、饲料及添加剂的研发、生产和销售。公司的主要产品是原料药、化药制剂、中药制剂、饲料及添加剂。","listedPrice":33.61},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"回盛生物(300871)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供回盛生物(300871)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"回盛生物,300871,回盛生物股票,回盛生物股票老虎,回盛生物股票老虎国际,回盛生物行情,回盛生物股票行情,回盛生物股价,回盛生物股市,回盛生物股票价格,回盛生物股票交易,回盛生物股票购买,回盛生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"回盛生物(300871)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供回盛生物(300871)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}